JAC Advance Access originally published online on September 1, 2005
Journal of Antimicrobial Chemotherapy 2005 56(4):738-744; doi:10.1093/jac/dki308
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals
1 Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK; 2 Department of G.U. Medicine, Royal Liverpool University Hospital, Liverpool, UK
Received 27 May 2005; returned 5 July 2005; revised 2 August 2005; accepted 4 August 2005
* Correspondence address. Pharmacology Research Labs, University of Liverpool, Block H, First Floor, 70 Pembroke Place, Liverpool, L69 3GF, UK. Tel: +44-151-794-5553; Fax: +44-151-794-5656; E-mail: lisaa{at}liv.ac.uk
Objectives: The site of action of efavirenz is inside HIV-infected cells. Measurement of intracellular (IC) concentrations of efavirenz may therefore provide further understanding of therapeutic failure, especially where virological rebound occurs despite adequate plasma levels, and a lack of detectable viral resistance. Here, we determined IC and plasma pharmacokinetics of efavirenz and their relationship with plasma protein binding and P-glycoprotein (P-gp, an active drug efflux transporter) expression.
Patients and methods: Venous blood samples from 10 HIV-infected patients receiving efavirenz (600 mg once a day plus two nucleoside reverse transcriptase inhibitors) were collected over the 24 h dosing interval. Plasma and peripheral blood mononuclear cells (PBMCs) were isolated. Plasma protein bound and unbound efavirenz were separated using ultrafiltration. IC (or cell-associated), total plasma and unbound plasma efavirenz levels were quantified using HPLC-UV. P-gp expression was measured by flow cytometry. Area under the concentration-time curves (AUC0–24) were then calculated using non-compartmental analyses and the IC accumulation expressed as a ratio of IC to plasma AUC0–24.
Results: The median (range) % unbound and IC accumulation ratio was 0.6% (0.4–1.5%) and 1.3 (0.7–3.3), respectively. There was a linear relationship between IC and total AUC0–24 (r2 = 0.59, P = 0.01) but not unbound AUC0–24 (r2 = 0.13, P = 0.75). An inverse correlation between IC AUC0–24 and % unbound was observed (r2 = 41, P = 0.05). There was no relationship between IC AUC0–24 and P-gp expression on the cell surface (r2 < 0.01, P = 0.98).
Conclusions: There was a direct relationship between % bound efavirenz in plasma and IC accumulation implying that the IC accumulation of efavirenz is related to binding to IC proteins or other cellular constituents. Studies investigating the unbound concentration of antiretrovirals inside the cell are now required.
Keywords: antiretrovirals , non-nucleoside reverse transcriptase inhibitors , NNRTIs
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Perez-Molina, P. Domingo, E. Martinez, and S. Moreno The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy J. Antimicrob. Chemother., August 1, 2008; 62(2): 234 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wyen, H. Hendra, M. Vogel, C. Hoffmann, H. Knechten, N. H. Brockmeyer, J. R. Bogner, J. Rockstroh, S. Esser, H. Jaeger, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients J. Antimicrob. Chemother., April 1, 2008; 61(4): 914 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tanaka, H. Hanabusa, E. Kinai, N. Hasegawa, M. Negishi, and S. Kato Intracellular Efavirenz Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Individuals Antimicrob. Agents Chemother., February 1, 2008; 52(2): 782 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Roucairol, S. Azoulay, M.-C. Nevers, C. Creminon, T. Lavrut, R. Garraffo, J. Grassi, A. Burger, and D. Duval Quantitative Immunoassay To Measure Plasma and Intracellular Atazanavir Levels: Analysis of Drug Accumulation in Cultured T Cells Antimicrob. Agents Chemother., February 1, 2007; 51(2): 405 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Friedland, S. Khoo, C. Jack, and U. Lalloo Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV J. Antimicrob. Chemother., December 1, 2006; 58(6): 1299 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Djabarouti, D. Breilh, I. Pellegrin, M. Lavit, F. Camou, O. Caubet, H. Fleury, M.-C. Saux, and J.-L. Pellegrin Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study) J. Antimicrob. Chemother., November 1, 2006; 58(5): 1090 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hossain and M. A. Parniak In Vitro Microbicidal Activity of the Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) UC781 against NNRTI-Resistant Human Immunodeficiency Virus Type 1 J. Virol., May 1, 2006; 80(9): 4440 - 4446. [Abstract] [Full Text] [PDF]
|
|